Clinical Trial to Evaluate Papilocare® Gel Efficacy Into Repairment of Cervical Lesions Caused by HPV

Inclusion Criteria: 1. Woman between the ages of 30 and 65 (both included). 2. Able to read and understand the Patient Information Sheet and informed consent 3. Accept participation in the study and sign the Informed Consent. 4. Cytological result of ASC-US or LSIL, with concordant colposcopic image, at most 3 months before the selection visit. It is considered concordant with ASCUS and LSIL, a colposcopic result of normality, of non-specific findings or of type 1 changes. 5. Positive HPV according to cobas 4800 technique (high-risk HPV) carried out in a selection visit (or positive available at most 3 months prior to the baseline visit). 6. Women vaccinated and not vaccinated against HPV. 7. Is able, at the discretion of the researcher, to comply with the requirements of the study and without impediments to follow the instructions and assessments throughout it. Exclusion Criteria: 1. Clinically relevant alterations of the immune system or any other autoimmune disease or in treatment with immunosuppressants. 2. Other cytological results other than those provided for in the inclusion criteria. 3. Baseline LSIL biopsies with CIN-3. 4. Abnormal undiagnosed genital bleeding (during the 6 months prior to the selection visit) 5. Other symptomatic vulvovaginal infections. 6. Surgical cervical excision in the last year or total hysterectomy. 7. Previous history of gynecological cancer. 8. Participation in any other clinical trial at present or in the 4 weeks prior to inclusion of the study. 9. Any planned surgery that precludes correct compliance with the guideline. 10. Use of vaginal contraceptives or other vaginal hormonal treatments. 11. Contraindications to the use of Papilocare® gel or known allergies to any of its components. 12. Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspected pregnancy or breastfeeding.